In The News Posted March 1, 2019 Share Posted March 1, 2019 INDIANAPOLIS, March 1, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that it will present data for Taltz® (ixekizumab) and mirikizumab at the American Academy of Dermatology (AAD) annual meeting taking place March 1-5, 2019 in Washington, DC. The data include 20... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.